Nucleus (Aug 2019)

Estimation of volumetric dose distribution delivery deviations vs. dose planned in <sup>131</sup>I hyperthyroidism treatment: preliminary results

  • Adlin López Díaz,
  • Juan Miguel Martín,
  • Amalia Pérez,
  • Eduardo O. Ramos Rodríguez

Journal volume & issue
Vol. 0, no. 65
pp. 1 – 5

Abstract

Read online

In 2013, the European Association of Nuclear Medicine Dosimetry Committee recommends a “Standard Operational Procedures for Hyperthyroidism Pre-Therapeutic Dosimetry” based on the assessment of the individual 131I uptake and kinetics. To estimate the 3D dose delivery deviations from prescribed dose during patient specific application of this SOP, a computer Matlab application was developed and verified. It was design to execute: radiopharmaceutical curve fitting, cumulated activity calculations, functional thyroid mass estimation, obtain the therapeutic planning activity to warranty the prescribed dose and produce the 3D planning dose map and related dosimetry parameters. 6 patients with 150-400Gy prescribed dose data planning (average 241,67Gy) were analysed using the developed application. The developed system was verify successfully using a test image phantom and 6 known pharmacokinetics data. The tridimensional thyroid volume cumulated activity and dose distributions were heterogeneous. 3D dose distribution showed standard deviations between 18.01-27.08 % of prescribed dose. The differences between maximum and minimum dose value per voxel/MBq were 74-129%. According to the result, between 50,2 % and 71,4 % of patient’s thyroid will be treat with a dose of DP±20 % of planned dose, the rest will be overdose or sub dose. Conclusions: the 3D treatment planning dose distribution were completely no-homogenous, the significant difference observed should be study in the future more deeply in order to optimized the hyperthyroidism iodine treatment.

Keywords